NBI 31772 is a nonpeptide ligand that releases insulin-like growth factor-1 (IGF-1) from its binding protein (IGFBP; Kis = 1-24 nM for the six human subtypes of IGFBP).1,2 As the released IGF-1 is biologically active, NBI 31772 is used to assess the role of IGF-1 in cells and animals, including in neuron survival, skeletal muscle regeneration, and glucose homeostasis.3,4,5
1.De Ceuninck, F., Caliez, A., Dassencourt, L., et al.Pharmacological disruption of insulin-like growth factor 1 binding to IGF-binding proteins restores anabolic responses in human osteoarthritic chondrocytesArthirits Res. Ther.6(5)R393-R403(2004) 2.Liu, X.-J., Xie, Q.W., Zhu, Y.-F., et al.Identification of a nonpeptide ligand that releases bioactive insulin-like growth factor-I from its binding protein complexJ. Biol. Chem.276(35)32419-32422(2001) 3.Hollis, E.R., II, Lu, P., Blesch, A., et al.IGF-I gene delivery promotes corticospinal neuronal survival but not regeneration after adult CNS injuryExp. Neurol.215(1)53-59(2009) 4.Schertzer, J.D., Gehrig, S.M., Ryall, J.G., et al.Modulation of insulin-like growth factor (IGF)-I and IGF-binding protein interactions enhances skeletal muscle regeneration and ameliorates the dystrophic pathology in mdx miceAm. J. Pathol.171(4)1180-1188(2007) 5.Silha, J.V., and Murphy, L.J.The effects of the insulin-like growth factor-I aptamer, NBI-31772, on glucose homeostasis in the mouseCan. J. Physiol. Pharmacol.83(7)557-563(2005)